Indaptus Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Indaptus Therapeutics, Inc. (INDP) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $150.61 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2025-11-12
- Indaptus Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $150.61K, a 66.09% decline year-over-year.
- Indaptus Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $180.76K, a 76.91% decline year-over-year.
- Indaptus Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $240.89K, a 68.90% decline year-over-year.
- Indaptus Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-09-30 was $444.18K, a 41.92% decline year-over-year.
- Indaptus Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $2.31M, a 22.26% decline from fiscal 2023.
- Indaptus Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $2.97M, a 0.29% increase from fiscal 2022.
- Indaptus Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $2.96M, a 95.81% increase from fiscal 2021.
- Indaptus Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $1.51M, a 979.06% increase from fiscal 2020.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2025-09-30 | $150.61K 10-Q · filed 2025-11-12 | $331.38K derived: sum of 2 quarters · filed 2025-11-12 | $572.27K derived: sum of 3 quarters · filed 2025-11-12 | ||
| 2025-06-30 | $180.76K 10-Q · filed 2025-11-12 | $421.65K derived: sum of 2 quarters · filed 2025-11-12 | |||
| 2025-03-31 | $240.89K 10-Q · filed 2025-11-12 | ||||
| 2024-12-31 | $2.31M 10-K · filed 2025-03-13 | ||||
| 2024-09-30 | $444.18K 10-Q · filed 2025-11-12 | $1.23M derived: sum of 2 quarters · filed 2025-11-12 | $2.00M derived: sum of 3 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $782.85K 10-Q · filed 2025-11-12 | $1.56M derived: sum of 2 quarters · filed 2025-11-12 | |||
| 2024-03-31 | $774.69K 10-Q · filed 2025-11-12 | ||||
| 2023-12-31 | $2.97M 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | $764.80K 10-Q · filed 2024-11-12 | $1.49M derived: sum of 2 quarters · filed 2024-11-12 | $2.22M derived: sum of 3 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $728.47K 10-Q · filed 2024-11-12 | $1.46M derived: sum of 2 quarters · filed 2024-11-12 | |||
| 2023-03-31 | $727.14K 10-Q · filed 2024-11-12 | ||||
| 2022-12-31 | $2.96M 10-K · filed 2024-03-13 | ||||
| 2022-09-30 | $584.04K 10-Q · filed 2023-11-06 | $1.49M derived: sum of 2 quarters · filed 2023-11-06 | $2.32M derived: sum of 3 quarters · filed 2023-11-06 | ||
| 2022-06-30 | $904.39K 10-Q · filed 2023-11-06 | $1.74M derived: sum of 2 quarters · filed 2023-11-06 | |||
| 2022-03-31 | $831.18K 10-Q · filed 2023-11-06 | ||||
| 2021-12-31 | $1.51M 10-K · filed 2023-03-17 | ||||
| 2021-09-30 | $795.34K 10-Q · filed 2022-11-10 | $816.01K derived: sum of 2 quarters · filed 2022-11-10 | $836.46K derived: sum of 3 quarters · filed 2022-11-10 | ||
| 2021-06-30 | $20.67K 10-Q · filed 2022-11-10 | $124.00K 10-Q · filed 2021-08-16 | $208.00K 10-Q · filed 2021-08-16 | ||
| 2021-03-31 | $20.45K 10-Q · filed 2022-11-10 | ||||
| 2020-12-31 | $139.96K 10-K · filed 2022-03-21 | ||||
| 2020-09-30 | $39.21K 10-Q · filed 2021-11-15 | $77.99K derived: sum of 2 quarters · filed 2021-11-15 | $116.87K derived: sum of 3 quarters · filed 2021-11-15 | ||
| 2020-06-30 | $38.78K 10-Q · filed 2021-11-15 | $414.00K 10-Q · filed 2021-08-16 | $856.00K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $38.88K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |